Hormonal Effects of the Oral Gonadotropin Releasing Hormone (GnRH) Antagonist at Different Periods of the Menstrual Cycle
- Sponsor
- University of Southern California
- Study ID
- NCT04060992
- Phase
- PHASE4
- Status
- Unknown
Conditions
- Ovulation; Failure or Lack of
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - 39 Years
- Healthy Volunteers
- Accepted
Interventions
- Elagolix 200 MG Oral Tablet [Orilissa] — DRUGoral tablet given twice daily
Study Details
The purpose of this study is twofold: First, to see if elagolix can suppress gonadotropin and ovarian hormones in the short-term period, when only administered for a 72-hour period. If elagolix effectively suppresses gonadotropin and ovarian hormones in a timely manner, it could be used to alter aspects of the menstrual cycle, depending on when administered. Second, is there a window for when elagolix functions best? While other studies initiate elagolix at the start of a woman's menstrual cycle, investigators of this study want to determine if administering elagolix at various points in a woman's menstrual cycle alters its ability to suppress gonadal and ovarian hormones.
Key Dates
- Start date
- Oct 1, 2019
- Status verified
- Aug 2019
- Primary completion
- Oct 30, 2020
- Completion
- Jul 1, 2021
Study Design
- Enrollment
- 12 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- SCREENING
Arms
- Experimental: Early Follicular PhaseWomen enrolled will be anywhere from cycle day 1 through 5 of their menstrual cycle and take elagolix 200mg oral tablet BID for 3 days total.
- Active Comparator: Late Follicular PhaseWomen enrolled will be anywhere from cycle day 8 through 13 of their menstrual cycle and take elagolix 200mg oral tablet BID for 3 days total.
- Active Comparator: Luteal PhaseWomen enrolled will be anywhere from cycle day 21 through cycle day 26 of their menstrual cycle and take elagolix 200mg oral tablet BID for 3 days total.
Primary Outcome Measure
Suppression of gonadotropin and pituitary hormones as measured by hormonal assay status post short-term administration of elagolix [ Time Frame: measured over 4 days ]
Central Contacts
- Rachel B Danis, MD5169931812
- Frank Stanczyk, PhD818-694-7522